Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using inverse probability of treatment weighting.

Naru Kondo Kenichiro UemuraTatsuaki SumiyoshiKenjiro OkadaShingo SeoHiroyuki OtsukaReo KawanoYoshiaki MurakamiShinya Takahashi

Published in: Journal of hepato-biliary-pancreatic sciences (2022)

Extended duration (≥30 weeks) of adjuvant GS chemotherapy in patients with PDAC was associated with an improved prognosis. These findings warrant a further prospective trial on PDAC to investigate the survival benefit of extended adjuvant chemotherapy.

Keyphrases

locally advanced
early stage
clinical trial
rectal cancer
radiation therapy
randomized controlled trial
phase ii
replacement therapy